Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection
The Journal of Infectious Diseases2010Vol. 201(6), pp. 803–813
Citations Over TimeTop 1% of 2010 papers
David A. Cooper, Jayvant Heera, James Goodrich, Margaret Tawadrous, Michael S. Saag, Edwin DeJesus, Nathan Clumeck, Sharon Walmsley, Naitee Ting, Eoin Coakley, Jacqueline D. Reeves, Gustavo Reyes‐Terán, Mike Westby, Elna van der Ryst, Prudence Ive, Lerato Mohapi, Horacio Mingrone, Andrzej Horban, Frances Hackman, John Sullivan, Howard Mayer
Abstract
Twice-daily maraviroc was not noninferior to efavirenz at <50 copies/mL in the primary analysis. However, 15% of patients would have been ineligible for inclusion by a more sensitive screening assay. Their retrospective exclusion resulted in similar response rates in both arms Trial registration. ClinicalTrials.gov identifier: (NCT00098293) .
Related Papers
- → Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1(2013)37 cited
- → Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study(2019)18 cited
- Maraviroc first-line therapy for HIV infection. Too risky.(2010)
- → PIN7 ANALYSIS OF THE EFFECTIVENESS OF ENHANCE ADHERENCE COUNSELLING (EAC) ON VIRALLY UNSUPPRESSED HIV PATIENTS IN ST CHARLES BORROMEO HOSPITAL, ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA.(2019)